Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

During the 43rd J.P. Morgan Annual Healthcare Conference last month, Areteia Therapeutics took centre stage, presenting a ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Targeted biologic drugs have revolutionized the treatment of severe asthma driven by eosinophils, which are white blood cells ...

Eosinophilic asthma (also known as e-asthma or eos asthma) is a severe form of asthma that causes high levels of eosinophils in the lung tissue, blood, and mucus. Eosinophils are a type of immune ...

The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

Exhaled Nitric Oxide and Sputum Eosinophils are Complementary Tools for Diagnosing Occupational Asthma suggests a study published in the Allergy.Exposure-related changes in exhaled nitric ...